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64 Abstract Aims/hypothesis: Glucose-dependent insulinotropic polypeptide
(GIP) and xenin, regulatory gut hormones secreted from
enteroendocrine K cells, exert important effects on metabolism. In
addition, xenin potentiates the biological actions of GIP. The
present study assessed the actions and therapeutic uti l i ty of a
(DAla2)GIP/xenin-8-Gln hybrid peptide, in comparison with the
parent peptides (DAla2)GIP and xenin-8-Gln.
Methods: Following confirmation of enzymatic stabil ity, insulin
secretory activity of (DAla2)GIP/xenin-8-Gln was assessed in BRIN
BD11 beta cells. Acute and persistent glucose-lowering and insulin-
releasing effects were then examined in vivo. Finally, the
metabolic benefits of twice daily injection of
(DAla2)GIP/xenin-8-Gln was determined in high-fat-fed mice.
Results: All peptides significantly (p < 0.05 to p < 0.001) enhanced
in vitro insulin secretion from pancreatic clonal BRIN-BD11 cells,
with xenin (and particularly GIP)-related signalling pathways, being
important for this action. Administration of (DAla2)GIP or
(DAla2)GIP/xenin-8-Gln in combination with glucose significantly
(p < 0.05) lowered blood glucose and increased plasma insulin in
mice, with a protracted response of up to 4 h. All treatments
elicited appetite-suppressive effects (p < 0.05), particularly
(DAla2)GIP/xenin-8-Gln and xenin-8-Gln at elevated doses of
250 nmol/kg. Twice-daily administration of (DAla2)GIP/xenin-8-Gln
or (DAla2)GIP for 21 days to high-fat-fed mice returned circulating
blood glucose to lean control levels. In addition,
(DAla2)GIP/xenin-8-Gln treatment significantly (p < 0.05) reduced
glycaemic levels during a 24 h glucose profile assessment. Neither
of the treatment regimens had an effect on body weight, energy
intake or circulating insulin concentrations. However, insulin
sensitivity was significantly (p < 0.001) improved by both treatments.
Interestingly, GIP-mediated glucose-lowering (p < 0.05) and insulin-
releasing (p < 0.05 to p < 0.01) effects were substantially improved
by (DAla2)GIP and (DAla2)GIP/xenin-8-Gln treatment. Pancreatic
islet and beta cell area (p < 0.001), as well as pancreatic insulin
content (p < 0.05), were augmented in (DAla2)GIP/xenin-8-Gln-
treated mice, related to enhanced proliferation and decreased
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apoptosis of beta cells, whereas (DAla2)GIP evoked increases (p < 
0.05 to p < 0.01) in islet number.
Conclusions/interpretation: These studies highlight the clear
potential of GIP/xenin hybrids for the treatment of type 2 diabetes.
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14 tide (GIP) and xenin, regulatory gut hormones secreted from
15 enteroendocrine K cells, exert important effects on metabo-
16 lism. In addition, xenin potentiates the biological actions of
17 GIP. The present study assessed the actions and therapeutic
18 utility of a (DAla2)GIP/xenin-8-Gln hybrid peptide, in com-
19 parison with the parent peptides (DAla2)GIP and xenin-8-Gln.
20 Methods Following confirmation of enzymatic stability, in-
21 sulin secretory activity of (DAla2)GIP/xenin-8-Gln was
22 assessed in BRIN BD11 beta cells. Acute and persistent
23 glucose-lowering and insulin-releasing effects were then
24 examined in vivo. Finally, the metabolic benefits of twice
25 daily injection of (DAla2)GIP/xenin-8-Gln was determined
26 in high-fat-fed mice.
27 Results All peptides significantly (p<0.05 to p<0.001) en-
28 hanced in vitro insulin secretion from pancreatic clonal BRIN-
29 BD11 cells, with xenin (and particularly GIP)-related signal-
30 ling pathways, being important for this action. Administration
31 of (DAla2)GIP or (DAla2)GIP/xenin-8-Gln in combination
32 with glucose significantly (p<0.05) lowered blood glucose
33 and increased plasma insulin in mice, with a protracted re-
34 sponse of up to 4 h. All treatments elicited appetite-
35 suppressive effects (p < 0.05), particularly (DAla2)GIP/
36xenin-8-Gln and xenin-8-Gln at elevated doses of 250 nmol/
37kg. Twice-daily administration of (DAla2)GIP/xenin-8-Gln
38or (DAla2)GIP for 21 days to high-fat-fed mice returned
39circulating blood glucose to lean control levels. In addi-
40tion, (DAla2)GIP/xenin-8-Gln treatment significantly
41(p< 0.05) reduced glycaemic levels during a 24 h glucose
42profile assessment. Neither of the treatment regimens had
43an effect on body weight, energy intake or circulating
44insulin concentrations. However, insulin sensitivity was
45significantly (p < 0.001) improved by both treatments.
46Interestingly, GIP-mediated glucose-lowering (p < 0.05)
47and insulin-releasing (p < 0.05 to p < 0.01) effects were
48substantially improved by (DAla2)GIP and (DAla2)GIP/
49xenin-8-Gln treatment. Pancreatic islet and beta cell area
50(p < 0.001), as well as pancreatic insulin content
51(p< 0.05), were augmented in (DAla2)GIP/xenin-8-Gln-
52treated mice, related to enhanced proliferation and de-
53creased apoptosis of beta cells, whereas (DAla2)GIP
54evoked increases (p< 0.05 to p< 0.01) in islet number.
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56potential of GIP/xenin hybrids for the treatment of type 2
57diabetes.
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72 Introduction
73 A defect in the postprandial insulin-secretory incretin re-
74 sponse, mediated by the gut hormones glucagon-like pep-
75 tide-1 (GLP-1) and glucose-dependent insulinotropic peptide
76 (GIP), is a specific pathophysiological characteristic of type 2
77 diabetes [1]. The main impairments are recognised as reduced
78 postprandial GLP-1 secretion and defective GIP receptor sig-
79 nalling [1]. The inadequacy in the GLP-1 arm of the incretin
80 effect can be easily overcome through administration of exog-
81 enous GLP-1, which significantly amplifies circulating con-
82 centrations [2, 3]. In contrast, pharmacological augmentation
83 of circulating GIP levels fails to evoke an effective increase in
84 insulin secretion in patients with type 2 diabetes [4]. As such,
85 it seems unlikely that stand-alone GIP-based drugs would
86 have therapeutic value for type 2 diabetes. Notwithstanding
87 this, strategies to overcome defective GIP action in type 2
88 diabetes would be of considerable interest.
89 Near normalisation of blood glucose levels has been shown
90 to restore the insulin-secretory effect of GIP in both animal
91 models of type 2 diabetes [5] and in humans [6] with this
92 condition, providing evidence that defective GIP receptor sig-
93 nalling is reversible. In addition, co-administration of GIP
94 with a sulfonylurea restores pancreatic beta cell sensitivity to
95 GIP [7], although this could be linked to uncoupling of
96 incretin glucose dependency by sulfonylureas [8]. More en-
97 couraging, recent studies have highlighted the possibility that
98 xenin, a hormone co-secreted with GIP from a subset of
99 enteroendocrine K cells, could amplify the insulin-secretory
100 response of GIP [9]. In agreement, observations from our
101 laboratory and others confirm the GIP-potentiating effects of
102 xenin under normal and type 2 diabetes conditions [10–13].
103 Furthermore, there is also evidence to suggest that xenin acts
104 as a satiety hormone in animals [10, 14–17] and humans [18].
105 As such, therapeutic interventions that combine the biological
106 actions of xenin and GIP, and potentially restore GIP action in
107 type 2 diabetes, would have particularly exciting potential.
108 There has been a recent upsurge in interest focused on gener-
109 ating designer hybrid peptides that can modulate multiple reg-
110 ulatory peptide hormone receptor pathways [19–22].
111 Successful generation of hybrid peptides has been achieved
112 through fusion of the key bioactive amino acid sequences of
113 the parent peptides [19–22]. This increases the therapeutic
114 applicability of gut-hormone-based drugs by facilitating for-
115 mulation and dosing with a single molecule, rather than co-
116 injection of separate parent peptide forms. For xenin, the nat-
117 urally occurring C-terminal fragment, known as xenin-8, re-
118 tains biological activity at the level of the endocrine pancreas
119 [13, 23]. Moreover, we have also shown that a stable analogue
120 of xenin-8, namely xenin-8-Gln, is biologically active and has
121 a spectrum of beneficial metabolic effects in vitro and in vivo
122 [24]. For GIP, the first 14 N-terminal amino acid residues
123 contain the bioactive domain important for insulin-secretory
124function [25, 26]. Based on this knowledge, we constructed a
125novel GIP/xenin hybrid peptide, (DAla2)GIP/xenin-8-Gln, by
126linking GIP(1-14) to xenin-8-Gln, retaining the regions of
127each peptide known to be important for biological activity
128(see electronic supplementary material [ESM] Table 1).
129Importantly, since GIP is a substrate for dipeptidyl
130peptidase-4 (DPP-4) [27], the hybrid peptide includes substi-
131tution of the naturally occurring alanine L isomer residue by a
132D isomer at position 2 [28, 29]. The results reveal that GIP/
133xenin hybrid molecules require further consideration as a
134treatment option for type 2 diabetes.
135Methods
136Peptide synthesisAll peptides (ESMTable 1) were purchased
137from GL Biochem (Shanghai, China; greater than 95% puri-
138ty). Peptides were characterised in-house using HPLC and
139matrix-assisted laser desorption ionisation time-of-flight
140(MALDI-TOF) mass spectrometry (ESM Table 2), as de-
141scribed previously [29].
142Assessment of DPP-4 degradation Peptide (20 μg) DPP-4
143degradation profiles (5 μl purified DPP-4, 5 mU; Sigma-
144Aldrich, UK) were assessed as described previously [29].
145Xenin-based peptides have been shown to be resistant to
146DPP-4 [10, 24].
147In vitro insulin secretion BRIN-BD11 cells were used to
148assess the insulin-releasing activity of test peptides, as de-
149scribed previously [30]. This hybrid cell line (ECACC
15010033003) was originally generated in-house by electrofusion
151of a primary culture of New England Deaconess Hospital
152(NEDH) rat pancreatic islets with RINm5F (a cell line derived
153from an NEDH rat insulinoma), and has been mycoplasma
154eradicated. For details of experimental conditions please see
155ESM Methods. Insulin was measured by radioimmunoassay
156[31].We assessed the impact of GIP and neurotensin receptors
157on (DAla2)GIP/xenin-8-Gln-induced insulin secretion in
158BRIN-BD11 cells. Cells were incubated in 5.6 mmol/l glucose
159with (DAla2)GIP/xenin-8-Gln (10−6 mol/l) alone or in combi-
160nation with the GIP receptor antagonist GIP(6-30)Cex-
161K40[Pal] [32] (where Pal is palmitate) or the neurotensin re-
162ceptor antagonist SR142984A (Tocris Bioscience,
163Avonmouth, UK), and insulin secretion determined as de-
164scribed above. In addition, to determine mechanisms, intracel-
165lular Ca2+ was also measured in BRIN-BD11 cells following
166treatment with test peptides (10−6 mol/l), using a Flexstation
167scanning fluorometer (FLIPR Calcium 5 assay kit; Molecular
168Devices, Sunnyvale, CA, USA), as described previously [10].
169Animals Acute and persistent dose-dependent animal studies
170were conducted in male albino NIH outbred Swiss mice
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171 (Envigo, Huntingdon, UK), that were derived from a nucleus
172 colony obtained from the National Institutes of Health,
173 Bethesda, Maryland. Longer-term experiments were conduct-
174 ed with male high-fat-fed NIH Swiss mice. For further details
175 of mice age and maintenance please see ESM.
176 Acute in vivo effects in lean mice Specific information on
177 acute feeding, glucose homeostasis and insulin-secretory stud-
178 ies is given in ESMMethods. To assess the impact of GIP and
179 neurotensin receptor activation on (DAla2)GIP/xenin-8-Gln-
180 induced glucose-lowering and insulin-secretory actions in
181 mice, (DAla2)GIP/xenin-8-Gln was administered by i.p. injec-
182 tion (25 nmol/kg body weight) in combination with glucose
183 (18 mmol/kg) in the absence and presence of GIP(6-30)Cex-
184 K40[Pal] and SR142984A (both at 25 nmol/kg), and glucose
185 and insulin were measured as described above. In a final series
186 of experiments, test peptides (25 nmol/kg) or saline vehicle
187 (0.9% wt/vol. NaCl) were injected 4 h before a glucose load
188 (18 mmol/kg) in non-fasted mice and blood glucose and plas-
189 ma insulin measured as above.
190 Subchronic in vivo studies in high-fat-fed mice Twice-daily
191 (09:30 and 17:30 hours) i.p. injections of saline vehicle,
192 (DAla2)GIP or (DAla2)GIP/xenin-8-Gln hybrid (both at
193 25 nmol/kg) were administered for 21 days in high-fat-fed
194 mice. Energy intake and body weight were monitored daily
195 and non-fasting blood glucose and plasma insulin concentra-
196 tions were assessed at 3 day intervals. On day 21, a non-fasted
197 24 h glucose profile was conducted. At the end of the treat-
198 ment period, i.p. glucose tolerance (18 mmol/kg), biological
199 response to GIP (18 mmol/kg glucose in combination with
200 native GIP [25 nmol/kg], i.p.) and insulin sensitivity (15 U/
201 kg; i.p.) tests were performed. Terminal analysis included
202 measurement of total body fat and lean mass by dual-energy
203 X-ray absorptiometry (DEXA) scanning (Piximus
204 Densitometer; Inside Outside Sales, Fitchburg, WI, USA)
205 and extraction of pancreatic tissue for analysis as detailed
206 below.
207 Immunohistochemistry Pancreas tissue was excised, divided
208 longitudinally and either snap frozen for extraction of insulin
209 using acid ethanol (5 ml/g), as described previously [22], or
210 processed for immunohistochemical examination.
211 Immunohistochemistry was performed as described previous-
212 ly [33]. For specific details, please see ESM Methods.
213 Biochemical analysis Blood samples were collected from the
214 cut tip on the tail vein of conscious mice into chilled fluoride/
215 heparin glucose micro-centrifuge tubes (Sarstedt, Numbrecht,
216 Germany). Blood glucose was measured directly using a
217 hand-held Ascencia Contour blood glucose meter (Bayer
218 Healthcare, Newbury, UK). Plasma and pancreatic insulin
219was assayed by a modified dextran-coated charcoal radioim-
220munoassay [31].
221Statistical analysis Statistical analysis was performed using
222GraphPad PRISM (La Jolla, CA, USA; version 5). For
223in vitro, islet histology and pancreatic insulin content studies,
224all samples were numbered and blinded. For acute and sub-
225chronic metabolic tests, there was no blinding. There were no
226inclusion and exclusion criteria applied. Results are expressed
227as means±SEM and data were compared using repeated mea-
228sures ANOVA followed by the Student–Newman–Keuls post
229hoc test. Groups of data were considered to be significantly
230different if p<0.05.
231Results
232In vitro studies In contrast to native GIP, (DAla2)GIP/xenin-
2338-Gln and (DAla2)GIP remained fully intact when incubated
234in the presence of DPP-4 for up to 12 h (ESM Table 2). All
235peptides significantly (p<0.05 to p<0.001) stimulated insulin
236secretion from BRIN-BD11 cells at a concentration of
23710−6 mol/l (Fig. 1a, b). Only (DAla2)GIP evoked a significant
238(p<0.01 to p<0.001) increase in insulin release at 10−8 mol/l
239when compared with respective glucose controls (Fig. 1a, b).
240As expected, the GIP receptor inhibitor GIP(6-30)Cex-
241K40[Pal] completely annulled (DAla2)GIP-mediated elevation
242of insulin secretion, while the neurotensin receptor inhibitor
243SR142948A had a similar, but less prominent, effect on xenin-
2448-Gln (Fig. 1c). As such, insulin concentrations were still
245significantly elevated (p < 0.05) following co-culture of
246xenin-8-Gln and SR142948A when compared with
2475.6 mmol/l glucose control (Fig. 1c). The insulinotropic effect
248of (DAla2)GIP/xenin-8-Gln was completely inhibited
249(p<0.001) by GIP(6-30)Cex-K40[Pal] and partially reversed
250(p< 0.05) by SR142984A (Fig. 1c). Neither, (DAla2)GIP,
251xenin-8-Gln nor (DAla2)GIP/xenin-8-Gln had any effect on
252intracellular Ca2+ concentrations (Fig. 1d).
253Acute in vivo food-intake studies At 25 nmol/kg,
254(DAla2)GIP/xenin-8-Gln induced a significant (p<0.05) re-
255duction in food intake at 30min post injection when compared
256with saline controls (Fig. 1e). None of the peptides had signif-
257icant appetite-suppressive effects when administered at
258100 nmol/kg (Fig. 1f). At a supraphysiological dose of
259250 nmol/kg, all peptides except (DAla2)GIP induced signif-
260icant (p<0.05 to p<0.01) reductions in food intake at 180min
261post injection (Fig. 1g). In addition, at 250 nmol/kg, the
262appetite-suppressive effect of xenin was significantly
263(p<0.05) superior to control mice at 90 min post injection,
264while xenin-8-Gln and (DAla2)GIP/xenin-8-Gln also evoked
265significant (p<0.05) reductions in food intake at 120 min
266(Fig. 1g).
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267 Acute and persistent glucose-lowering and insulin-
268 releasing effects in lean mice Administration of xenin-8-
269 Gln, (DAla2)GIP or (DAla2)GIP/xenin-8-Gln concomitantly
270 with glucose resulted in significantly (p<0.05) lowered blood
271 glucose values at 30 min post injection, culminating in signif-
272 icantly (p<0.05) decreased overall AUC blood glucose values
273 when compared with controls (Fig. 2a). (DAla2)GIP also in-
274 duced a significant (p<0.05) reduction in blood glucose levels
275 15 min post injection (Fig. 2a). Corresponding glucose-
276 induced plasma insulin concentrations were not altered be-
277 tween groups in terms of individual values, although overall
278glucose-stimulated plasma insulin levels were significantly
279(p<0.05) increased in all treatment groups compared with
280controls (Fig. 2b). The beneficial (p<0.01) acute glucose-
281lowering effect of (DAla2)GIP/xenin-8-Gln was blocked by
282both GIP(6-30)Cex-K40[Pal] and SR142948A (Fig. 2c),
283whereas only GIP(6-30)Cex-K40[Pal] impaired (DAla2)GIP/
284xenin-8-Gln-induced insulinotropic actions (Fig. 2d). When
285administered 4 h prior to a glucose load, xenin-8-Gln was
286devoid of glucose-lowering or insulin-releasing effects
287(Fig. 2e, f). However, when administered 4 h previously, both
288(DAla2)GIP and (DAla2)GIP/xenin-8-Gln significantly
b
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289 reduced the overall AUC for blood glucose (p<0.05) and
290 increased plasma insulin AUC (p<0.05) following a glucose
291 challenge (Fig. 2e, f).
292 Effects of twice-daily administration of (DAla2)GIP and
293 (DAla2)GIP/xenin-8-Gln on energy intake, body weight,
294 non-fasted blood glucose and plasma insulin in high-fat-
295 fed mice Twice-daily administration of (DAla2)GIP or
296 (DAla2)GIP/xenin-8-Gln for 21 days to high-fat-fed mice
297 had no significant effect on cumulative energy intake or body
298 weight compared with high-fat-fed controls (Fig. 3a, c). In
299 addition, total body fat and leanmass were also unaltered after
300 the 21 day regimen (Fig. 3b). However, all high-fat fed mice
301 exhibited significantly increased (p<0.05 to p<0.001) body
302 weight and cumulative energy intake compared with lean con-
303 trols (Fig. 3a, c). Non-fasting blood glucose levels progres-
304 sively declined in (DAla2)GIP/xenin-8-Gln-treated high-fat
305 fed mice over the 21 days, being significantly (p<0.05 to
306 p<0.01) reduced on observation days 3, 6 and 15 compared
307 with levels in control high-fat mice (Fig. 3d). Both
308 (DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated mice had
309 glucose levels that were not significantly different from lean
310 controls from day 12 onwards (Fig. 3d). Analysis of non-
311 fasting 24 h glucose profile on day 21 revealed that
312 (DAla2)GIP/xenin-8-Gln treated mice had similar blood glu-
313 cose levels to lean controls at each observation point and sig-
314 nificantly (p<0.05) reduced levels compared with high-fat-
315 fed controls at 17:00 hours (Fig. 3e). Blood glucose levels in
316(DAla2)GIP-treated mice were also reduced, but not to the
317same extent as in (DAla2)GIP/xenin-8-Gln mice (Fig. 3e).
318Circulating plasma insulin levels were generally elevated in
319all high-fat-fed mice compared with lean controls (Fig. 3f).
320Mice treated twice daily with either (DAla2)GIP or
321(DAla2)GIP/xenin-8-Gln did have reduced plasma insulin
322levels compared with high-fat-fed controls on day 21 but the
323difference did not reach statistical significance (Fig. 3f).
324Effects of twice-daily administration of (DAla2)GIP and
325(DAla2)GIP/xenin-8-Gln on glucose tolerance and meta-
326bolic response to GIP in high-fat-fed mice Treatment with
327(DAla2)GIP or (DAla2)GIP/xenin-8-Gln for 21 days reduced
328overall AUC for blood glucose levels of high-fat-fed mice fol-
329lowing a glucose load but the difference failed to reach statisti-
330cal significance (Table 1). Similarly, glucose-stimulated plasma
331insulin AUCs were reduced non-significantly by (DAla2)GIP
332or (DAla2)GIP/xenin-8-Gln treatment compared with high-fat
333controls (Table 1). All high-fat-fed mice had a significantly
334(p<0.05 to p<0.001) increased glycaemic excursion and over-
335all insulin-secretory response compared with lean controls
336(Table 1). As illustrated in Table 1, (DAla2)GIP and
337(DAla2)GIP/xenin-8-Gln treatment significantly (p<0.05) im-
338proved the glucose-lowering and insulin-releasing actions of
339native GIP; overall blood glucose AUC values were significant-
340ly (p<0.05) decreased by 36% and 30%, respectively, com-
341pared with saline-treated control. Moreover, AUCs for
342glycaemic values were not different when compared with lean
343controls in response to administration of GIP in combination
344with glucose (Table 1). Corresponding GIP-induced elevations
345of plasma insulin concentrations were also significantly
346(p < 0.05 to p < 0.01) augmented in (DAla2)GIP- and
347(DAla2)GIP/xenin-8-Gln-treated high-fat-fed mice compared
348with high-fat-fed controls (Table 1).
349Effects of twice-daily administration of (DAla2)GIP and
350(DAla2)GIP/xenin-8-Gln on insulin sensitivity and pancre-
351atic insulin content in high-fat fed mice Individual blood
352glucose levels were reduced, albeit non-significantly, in
353(DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated high-fat-
354fed mice following administration of exogenous insulin
355(Fig. 4a). However, the overall glucose-lowering effect of
356insulin was significantly (p < 0.001) improved in
357(DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated mice
358compared with control high-fat mice (Fig. 4b). The pancre-
359atic insulin content of (DAla2)GIP/xenin-8-Gln-treated
360mice was augmented (p< 0.05) compared with that of lean
361controls but was not significantly different from that of
362high-fat controls (Fig. 4c). In contrast, the pancreatic insu-
363lin content of (DAla2)GIP-treated mice was similar to that
364of lean control mice (Fig. 4c).
Fig. 1 Effects of peptides on insulin release and intracellular Ca2+
concentrations in BRIN-BD11 cells and on cumulative food intake in
lean control mice. (a, b) BRIN-BD11 cells were incubated (20 min)
with test peptides in the presence of 5.6 mmol/l glucose (a) or
16.7 mmol/l glucose (b). Light-grey bars, glucose controls; white bars,
xenin-8-Gln; dark-grey bars, (DAla2)GIP; black bars, (DAla2)GIP/xenin-
8-Gln. (c) Effects of the GIP and neurotensin receptor antagonists, GIP(6-
30)Cex-K40[Pal] and SR142984A, respectively, on (DAla2)GIP-, xenin-
8-Gln- and (DAla2)GIP/xenin-8-Gln-mediated (20 min) insulin release in
BRIN-BD11 cells. White bars, incubation in 5.6 mmol/l glucose alone;
black bars, glucose plus GIP(6-30)Cex-K40[Pal] (10−6 mol/l); grey bars,
glucose plus SR142948A (10−6 mol/l). (d) BRIN-BD11 cells were
incubated with 5.6 mmol/l glucose in the presence of test peptides
(10−6 mol/l) and intracellular Ca2+ concentrations were assessed over a
5 min period, with alanine (10 mmol/l) as positive control. AUC (0–
300 s) data is shown in the inset. Black circles and light-grey bars,
5.6 mmol/l glucose control; black squares and striped bars, 10 mmol/l
alanine; white circles and white bars, xenin-8-Gln; white squares and
dark-grey bars, (DAla2)GIP; black triangles and black bars,
(DAla2)GIP/xenin-8-Gln. (e–g) Cumulative food intake was measured
after i.p. injection of peptides at 25 (e), 100 (f) and 250 nmol/kg (g) in
overnight-fasted (18 h) lean control mice. Black bars, saline control;
diagonally striped bars, xenin-8; dark-grey bars, xenin-25; horizontally
striped bars, xenin-8-Gln; light-grey bars, (DAla2)GIP; white bars,
(DAla2)GIP/xenin-8-Gln. Values represent means ± SEM (n = 8).
*p < 0.05, **p < 0.01 and ***p < 0.001 compared with respective
glucose (a–d) or saline controls (e–g); †p < 0.05 and †††p < 0.001
compared with incubations in the absence of GIP or neurotensin
receptor antagonists, as appropriate
R
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365 Effects of twice-daily administration of (DAla2)GIP and
366 (DAla2)GIP/xenin-8-Gln on pancreatic islet histology in
367 high-fat-fed mice Representative images of pancreatic islets
368 from each mouse group are shown in Fig. 5a–d. High-fat-fed
369 mice had significantly (p<0.01) increased islet area compared
370 with lean controls (Fig. 5e), giving rise to significant (p<0.01)
371 increases in both beta and alpha cell areas (Fig. 5f, g). Treatment
372 with (DAla2)GIP had no significant effect on overall pancreatic
373 area or beta cell area but resulted in decreased (p<0.001) alpha
374 cell area compared with high-fat-fed controls (Fig. 5e–g).
375 Similarly, 21 days of twice-daily treatment with (DAla2)GIP/
376 xenin-8-Gln significantly (p<0.001) reduced pancreatic alpha
377 cell area compared with high-fat-fed controls (Fig. 5g). It also
378 increased (p<0.001) pancreatic islet and beta cell area compared
379 with lean controls (Fig. 5e, f). The number of islets per mm2was
380 significantly (p<0.05 to p<0.01) augmented in (DAla2)GIP-
381treated mice compared with all other groups (Fig. 5h). This
382effect appeared to be related to an increase in number of
383small-sized islets (Fig. 5i). Thus, high-fat feeding significantly
384(p<0.001) decreased the number of small islets and increased
385the number of large islets, compared with lean controls (Fig. 5i).
386(DAla2)GIP/xenin-8-Gln-treated high-fat-fed mice also had a
387decreased (p<0.001) number of small- andmedium-sized islets,
388and fewer (p<0.001) large islets, when compared with lean
389controls (Fig. 5i). Representative images of Ki67 and TUNEL
390immunostained pancreatic islets from each group of mice are
391shown in Fig. 6a–h. Proliferation and apoptosis rates of pancre-
392atic islet cells appeared to be relatively high in this strain of
393mouse. The rate of beta cell proliferation in (DAla2)GIP/xenin-
3948-Gln-treated high-fat-fed mice was significantly (p<0.05 to
395p<0.01) increased when compared with the rate in all other
396groups (Fig. 6i). In addition, the frequency of beta cell
0 15 30 45 60
0
5
10
15
20
Time (min)
Bl
oo
d 
gl
u
co
se
 (m
m
ol
/l)
0 15 30 45 60
40
60
80
100
Time (min)
Pl
as
m
a 
in
su
lin
 
(pm
ol
/l)0
200
400
600
800
1000
*
*
Bl
oo
d 
glu
co
se
 
AU
C
(m
m
ol
/l ×
 
m
in
)
0
1000
2000
3000
4000
5000 *
*
Pl
as
m
a 
in
su
lin
 
AU
C
(pm
ol/
l ×
 
m
in
)
a b c
d
0 15 30 45 60 75 90 105
5
10
15
20
25
*
*
*
*
Time (min)
Pl
as
m
a 
gl
u
co
se
 
(m
m
ol
/l)
0
500
1000
1500
2000
*
* *
Pl
as
m
a 
glu
co
se
 
AU
C
(m
m
ol/
l ×
 
m
in
)
0 15 30 45 60 75 90 105
20
40
60
80
100
Time (min)
Pl
as
m
a 
in
su
lin
 
(pm
ol
/l) 0
2000
4000
6000
8000
**
Pl
as
m
a 
in
su
lin
 A
UC
(pm
ol
/l ×
 
m
in
) *
0
200
400
600
800
**
†††
Bl
oo
d 
gl
u
co
se
 A
UC
(m
m
ol
/l 
× 
m
in
)
0
1000
2000
3000
4000
**
Time (min)
Pl
as
m
a 
in
su
lin
 A
UC
(pm
ol
/l 
× 
m
in
)
e f
Fig. 2 Acute and persistent glucose-lowering and insulin-releasing ef-
fects of (DAla2)GIP, xenin-8-Gln and (DAla2)GIP/xenin-8-Gln in lean
control mice. (a, b) Blood glucose (a) and plasma insulin (b) concentra-
tions were measured before and after i.p. injection of glucose alone
(18 mmol/kg) or in combination with peptides (each at 25 nmol/kg) in
non-fasted mice. AUCs are shown in insets. (c, d) Overall AUCs for
blood glucose (c) and plasma insulin (d) were measured before and after
i.p. injection of (DAla2)GIP/xenin-8-Gln. (25 nmol/kg) in combination
with glucose (18 mmol/kg) in the absence or presence of GIP(6-30)Cex-
K40[Pal] and SR142984A (both at 25 nmol/kg) in non-fasted mice. (e, f)
Blood glucose (e) and plasma insulin (f) concentrations were measured
following an i.p. glucose load (18 mmol/kg) in non-fasted mice injected
with saline vehicle or peptides (each at 25 nmol/kg) 4 h previously. AUCs
are shown in insets. Black circles and white bars, glucose alone (a–d) or
saline control (e, f); white triangles and dark-grey bars, glucose (a, b) or
saline (e, f) in combination with (DAla2)GIP; white squares and light-
grey bars, glucose (a, b) or saline (e, f) in combination with xenin-8-Gln;
black squares and black bars, glucose (a–d) or saline (c, d) in combination
with (DAla2)GIP/xenin-8-Gln; horizontal striped bars, (DAla2)GIP/
xenin-8-Gln in combination with GIP(6-30)Cex-K40[Pal]; diagonally
striped bars, (DAla2)GIP/xenin-8-Gln in combination with SR142948A.
Values represent means ± SEM for 7 or 8 mice. *p < 0.05 and **p< 0.01
compared with glucose alone (a, b) or saline control (c, d); †p< 0.05 and
††p< 0.01 compared with (DAla2)GIP/xenin-8-Gln group
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397 apoptosis was significantly (p < 0.01) decreased in
398 (DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated high-fat-
399fed mice compared with high-fat-fed controls, and was similar
400to levels in lean control mice (Fig. 6j).
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Q1 Fig. 3 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on body weight, body composition, cumulative
energy intake, non-fasted blood glucose, 24 h blood glucose profile and
non-fasted plasma insulin in high-fat-fed mice. (a, c, d, f) Variables were
measured for 3 days before and 21 days during (indicated by black hor-
izontal line) twice-daily treatment with saline vehicle, (DAla2)GIP or
(DAla2)GIP/xenin-8-Gln hybrid (each at 25 nmol/kg). (b, e) Total fat
and lean mass (b) and 24 h glucose profile (e) were assessed on day 21.
Arrows indicate timing of normal twice-daily injections. White squares
and light-grey bars, saline control; white circles and dark-grey bars,
(DAla2)GIP; black circles and black bars, (DAla2)GIP/xenin-8-Gln; black
triangles and white bars, lean control. Values represent means ± SEM for
6–8 mice. *p< 0.05, **p< 0.01 and ***p < 0.001 compared with high-
fat-fed controls. †p < 0.05, ††p < 0.01 and †††p< 0.01 compared with lean
controls
t1:1 Table 1 Effects of twice-daily
administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on
glucose tolerance,
glucose-stimulated insulin and
GIP-mediated glucose-lowering
and insulin-secretory actions in
high-fat-fed mice
t1:2 Treatment group Glucose tolerance test Metabolic response to GIP
t1:3 Blood glucose
AUC
(mmol/l ×min)
Plasma insulin
AUC
(pmol/l ×min)
Blood glucose
AUC
(mmol/l ×min)
Plasma insulin
AUC
(pmol/l ×min)
t1:4 High-fat saline control 2062.0 ± 121.2 16,377± 3063 16,18.9 ± 148.1 9770± 2024
t1:5 (DAla2)GIP 1714.7 ± 138.6† 11,253 ± 1590† 1029.5 ± 138.0* 20,308± 3805**,†††
t1:6 (DAla2)GIP/xenin-8-Gln 1757.3 ± 154.6† 8423 ± 1121† 1130.1 ± 143.9* 17,741± 4016*,††
t1:7 Lean control 1080.5 ± 85.7*** 4237 ± 232.6* 787.4 ± 54.2** 3611 ± 411.9
Values represent means ± SEM for 6–8 mice. AUC values (0–105 min) for blood glucose and plasma insulin are
shown
Tests were conducted after twice-daily treatment with saline vehicle, (DAla2 )GIP or (DAla2 )GIP/xenin-8-Gln
(each at 25 nmol/kg) for 21 days. For glucose tolerance test, blood glucose and plasma insulin concentrations were
measured before and 15, 30, 60 and 105min after i.p injection of glucose (18mmol/kg). For metabolic response to
GIP, blood glucose and plasma insulin concentrations were measured before and 15, 30, 60 and 105 min after i.p
injection of glucose (18 mmol/kg) in combination with GIP (25 nmol/kg). All studies were conducted in mice
fasted for 18 h
*p< 0.05, **p < 0.01 and **p< 0.01 compared with high-fat controls; † p< 0.05, †† p< 0.01 and ††† p< 0.001
compared with lean controls
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401 Discussion
402 Despite encouraging preclinical data and the success of DPP-4
403 inhibitors [34, 35], progression of enzyme-resistant GIP-based
404drugs to the type 2 diabetes clinic is lacking. Therefore, in the
405present study we have evaluated the biological actions and
406therapeutic applicability of a novel GIP/xenin hybrid peptide,
407namely (DAla2)GIP/xenin-8-Gln.
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Fig. 5 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on pancreatic histology. (a–d) Representative
images of islets showing insulin (red) and glucagon (green) immunore-
activity from pancreatic tissues extracted from high-fat-fed saline control
mice (a), (DAla2)GIP- (b) and (DAla2)GIP/xenin-8-Gln-treated high-fat-
fedmice (c) and lean control mice (d). (e–i) Variables were assessed using
CellF image analysis software after 21 days of twice-daily i.p injections of
saline vehicle or peptides (each at 25 nmol/kg) in high-fat-fed mice.
Light-grey bars, saline control; dark-grey bars, (DAla2)GIP; black bars,
(DAla2)GIP/xenin-8-Gln; white bars, lean control (e–h). White bars,
small islets (<10,000 μm2); grey bars, medium islets (10,000–
25,000 μm2); black bars, large islets (>25,000 μm2) (i). Values are
means ± SEM of 6–8 mice. Scale bar, 50 μm. *p < 0.05, **p< 0.01 and
***p < 0.001 compared with high-fat-fed controls. †p < 0.05 and
†††p < 0.001 compared with lean controls; ‡‡p < 0.01 and ‡‡‡p < 0.001
compared with the (DAla2)GIP group
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Fig. 4 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on insulin sensitivity and pancreatic insulin
content in high-fat-fed mice. Insulin (15 U/kg) was given by i.p. injection
(t = 0) in non-fasted mice following 21 days treatment with saline vehicle,
(DAla2)GIP or (DAla2)GIP/xenin-8-Gln hybrid (each at 25 nmol/kg).
Blood glucose was measured (a), area above the curve (AAC) was cal-
culated using identical baseline subtraction for each group (b) and
pancreatic insulin content was measured by RIA (c). White squares and
light-grey bars, saline control; white circles and dark-grey bars,
(DAla2)GIP; black circles and black bars, (DAla2)GIP/xenin-8-Gln; black
triangle and white bars, lean control. Values represent means ± SEM for
6–8mice. *p< 0.05, **p< 0.01 and ***p < 0.001 compared with high-fat
controls; †p < 0.05 compared with lean controls
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408 In harmony with previous studies [28, 29], (DAla2)GIP and
409 the hybrid peptide (DAla2)GIP/xenin-8-Gln were completely re-
410 sistant to degradation byDPP-4, indicating that the N-terminal D-
411 Ala2 modification employed effectively masked the DPP-4 bind-
412 ing site. As expected, the parent peptides, (DAla2)GIP and xenin-
413 8-Gln, stimulated insulin release from clonal pancreatic BRIN-
414 BD11 beta cells at physiological and elevated glucose concen-
415 trations [24, 29]. To determine the influence of both GIP and
416 xenin pathways on induction of bioactivity by (DAla2)GIP/
417 xenin-8-Gln, we utilised the specific GIP receptor antagonist
418 GIP(6-30)Cex-K40[Pal] [32] and the commercially available
419 neurotensin receptor antagonist, SR142984A. Reassuringly,
420 (DAla2)GIP/xenin-8-Gln was equally effective in vitro as an in-
421 sulin secretagogue as either of the parent peptides. Its
422 insulinotropic effects appeared to be more dependent on activa-
423 tion of GIP receptor-related cell signalling pathways, when com-
424 pared with xenin. In full agreement, the acute in vivo
425 insulinotropic actions of (DAla2)GIP/xenin-8-Gln were also
426 chiefly dependent upon activation of GIP receptor pathways.
427 Interestingly, the acute glucose-lowering actions of
428(DAla2)GIP/xenin-8-Gln appeared to be associated with activa-
429tion of both GIP and xenin pathways, suggesting possible
430insulin-independent glucose-lowering effects of xenin [12].
431However, the main effect of the xenin component of
432(DAla2)GIP/xenin-8-Gln likely relates to enhancement of GIP-
433mediated biological actions, as demonstrated here and previously
434[10, 11]. Full clarification of the mechanism of (DAla2)GIP/
435xenin-8-Gln-induced insulin release is necessary, but similar
436(DAla2)GIP/xenin-8-Gln-induced acute insulin-secretory effects
437were also noted in lean control mice, confirming biological effi-
438cacy. Our previous studies using clonal beta cells have shown
439that (DAla2)GIP activates adenylate cyclase pathways, whereas
440xenin-based peptides likely operate through the action of phos-
441pholipase C [10]. Further to this, we have shown that neither
442(DAla2)GIP/xenin-8-Gln nor its parent peptides significantly af-
443fected intracellular Ca2+ levels in BRIN-BD11 beta cells.
444In accordance with preserved bioactivity of the hybrid pep-
445tide, we observed satiety effects of (DAla2)GIP/xenin-8-Gln
446even at the lowest dose examined and especially at elevated
447doses. This is in agreement with previous findings suggesting
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Fig. 6 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on beta cell proliferation and apoptosis. (a–d)
Representative images showing insulin (green) and Ki67 (red, indicated
by arrows) in islets from high-fat-fed saline control mice (a), (DAla2)GIP-
(b) and (DAla2)GIP/xenin-8-Gln-treated high-fat-fed mice (c) and lean
control mice (d). (e–h) Representative images showing insulin (red) and
TUNEL (green, indicated by arrows) immunoreactivity in islets from
high-fat-fed saline control mice (e), (DAla2)GIP- (f) and (DAla2)GIP/
xenin-8-Gln-treated high-fat-fed mice (g) and lean control mice (h). (i,
j) Quantification of beta cell proliferation (i) and apoptosis frequency (j)
expressed as a percentage of beta cells analysed. Light-grey bars, saline
control; dark-grey bars, (DAla2)GIP; black bars, (DAla2)GIP/xenin-8-
Gln; white bars, lean control. Approximately 5000 beta cells per experi-
mental group were counted. Values are means ± SEM of 6–8 mice. Scale
bar, 50 μm. **p < 0.01 compared with high-fat-fed controls; †††p< 0.001
compared with lean controls; ‡p< 0.05 compared with (DAla2)GIP group
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448 that elevated doses of xenin are required to impart significant
449 appetite-suppressive activity, whereas lower doses have ben-
450 eficial metabolic effects [10, 13]. The persistence of the met-
451 abolic actions of (DAla2)GIP/xenin-8-Gln was then assessed.
452 Even 4 h after a single injection of (DAla2)GIP/xenin-8-Gln or
453 (DAla2)GIP, glucose-lowering and insulin-releasing actions
454 were clearly evident. This presumably relates to enhanced
455 enzymatic stability of (DAla2) modified GIP-forms and corre-
456 sponds well with the findings of other studies [28, 29].
457 Development of a specific assay to directly measure
458 (DAla2)GIP/xenin-8-Gln in plasma would be useful to deter-
459 mine the pharmacokinetic profile of the hybrid peptide.
460 Moreover, methodology such as peptide acylation or
461 PEGylation may help to extend the biological half-life of
462 (DAla2)GIP/xenin-8-Gln [29, 36]. Notably, the biological ef-
463 fects of (DAla2)GIP/xenin-8-Gln were equal, or indeed en-
464 hanced, when compared with either parent peptide administered
465 at the same dose. This indicates that the hybrid peptide still fully
466 retained the ability to activate GIP- and xenin-related cellular
467 signalling pathways involved in glucose homeostasis, insulin
468 secretion and appetite suppression [13, 29]. Taken together,
469 these data provided a strong basis for the subsequent 21 day
470 twice-daily injection regimen conducted in high-fat-fed mice.
471 Chronic treatment of high-fat-fed mice with (DAla2)GIP
472 resulted in sustained and significant reductions of circulating
473 blood glucose levels, both in terms of individual observation
474 points and during assessment of a 24 h blood glucose profile
475 [28, 29]. Crucially, (DAla2)GIP/xenin-8-Gln had equal or im-
476 proved beneficial effects on glycaemic status in high-fat mice.
477 Indeed, reductions in glucose levels were much more apparent
478 in mice treated with (DAla2)GIP/xenin-8-Gln during assessment
479 of the more-in-depth 24 h blood glucose profile. Interestingly,
480 significantly greater reductions in insulin-induced blood glucose
481 levels were observed in (DAla2)GIP/xenin-8-Gln- and
482 (DAla2)GIP-treated mice. This clearly points towards beneficial
483 effects of both treatments that are additional to effects on pan-
484 creatic beta cell function. This improvement of insulin action
485 was not a consequence of reduced adipose tissue mass. Thus,
486 it presumably reflects alleviation of glucotoxicity, or the actions
487 of GIP to improve insulin resistance [29, 37]. However, further
488 investigations, including euglycaemic–hyperinsulinaemic
489 clamps, glucose uptake and gene and protein expression studies,
490 are required to fully address the molecular mechanisms under-
491 pinning this benefit. Somewhat surprisingly, at the dose tested,
492 (DAla2)GIP/xenin-8-Gln had no effect on energy intake, al-
493 though similar observations have been reported previously with
494 xenin-based drugs [38]. This limited satiety effect presumably
495 reflects the requirement of supraphysiological doses of xenin to
496 impart appetite-suppressive effects [10]. However, it could also
497 be related to factors such as the palatability of the high-fat diet,
498 the age and strain of mice employed or the duration of the study.
499 As expected, a key component of the beneficial action of
500 (DAla2)GIP/xenin-8-Gln concerned the stimulation of beta
501cell function [13, 29]. Circulating and glucose-induced plasma
502insulin concentrations were significantly elevated compared
503with those in lean control mice, despite non-fasting glucose
504levels being similar. Moreover, the pancreatic insulin content
505was persistently higher in (DAla2)GIP/xenin-8-Gln-treated
506high-fat-fed mice. In agreement, pancreatic islet and beta cell
507areas were increased in (DAla2)GIP/xenin-8-Gln-treated
508mice, in line with the proliferative and anti-apoptotic beta cell
509actions of (DAla2)GIP/xenin-8-Gln, as has previously been
510reported for GIP [39, 40]. Consistent with our observations,
511the positive actions of GIP on islet and beta cell architecture
512have previously been shown to improve beta cell function and
513glycaemic control in animal models of type 2 diabetes [41].
514Interestingly, there is a recent suggestion that xenin may in-
515hibit GLP-1 secretion under certain circumstances [42].
516However, such observations still need to be fully confirmed
517and the current findings would not indicate any obvious det-
518rimental effects linked to reduced GLP-1 secretion or action
519by (DAla2)GIP/xenin-8-Gln.Moreover, GIP is known to stim-
520ulate GLP-1 secretion from the gut [43] as well as pancreatic
521alpha cells [44], affording GIP/xenin hybrids a clear advan-
522tage over xenin monotherapies. In keeping with improved
523beta cell dynamics in (DAla2)GIP/xenin-8-Gln-treated mice,
524the insulin-secretory and subsequent glucose-lowering effects
525of native GIP were substantially enhanced in these mice. As
526expected, the biological action of GIP was severely perturbed
527in high-fat-fed mice, akin to the situation in patients with type
5282 diabetes [4]. It would be more than reasonable to link a
529major part of the positive therapeutic effects of (DAla2)GIP/
530xenin-8-Gln directly to augmentation of GIP action, as previ-
531ously observed with other xenin-related compounds [10, 38].
532Thus, the main rationale for inclusion of the xenin component
533of our novel hybrid peptide was essentially to enhance GIP-
534mediated actions [10, 38]. However, normalisation of blood
535glucose levels, as clearly demonstrated in both (DAla2)GIP-
536and (DAla2)GIP/xenin-8-Gln-treated mice, has also been
537shown to independently restore GIP insulin-secretory function
538in type 2 diabetes [5, 6]. In addition, we have already confirmed
539that xenin has significant glucose-lowering activity independent
540of theGIP receptor [38]. Therefore, further studies are required to
541systematically assess the direct and indirect beneficial effects of
542(DAla2)GIP/xenin-8-Gln in restoring GIP action in type 2
543diabetes.
544Interestingly, both activation and inhibition of GIP receptors
545has been postulated as a possible treatment option for type 2
546diabetes and obesity [45]. Thus, GIP receptor agonism augments
547beta cell-induced glucose-dependent insulin secretion, akin to
548the actions of clinically approved GLP-1 mimetics [3]. This
549approach is very encouraging given that the issue of GIP sensi-
550tivity in type 2 diabetes is now being addressed. However, GIP
551is also believed to play a role in lipid metabolism and fat depo-
552sition [45]. Accordingly, GIP receptor antagonism can potential-
553ly protect against or even reverse many of the obesity-associated
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554 abnormalities of type 2 diabetes [46–48]. Similar to the conun-
555 drum regarding the clinical use of GIP receptor agonists or an-
556 tagonists, both genetic knockout [49] and overexpression [50] of
557 GIP has been shown to protect against obesity and development
558 of diabetes. Taken together, this likely reflects the plasticity of
559 cellular pathways linked to the regulation of energy balance.
560 Nonetheless, it is clear from the current study that novel treat-
561 ment options aimed at overcoming GIP resistance in type 2
562 diabetes have therapeutic potential.
563 In conclusion, the present study has demonstrated that the
564 novel hybrid peptide analogue (DAla2)GIP/xenin-8-Gln has
565 an impressive profile of beneficial metabolic effects in high-
566 fat-fed mice, including improvement of glucose tolerance, in-
567 sulin resistance and pancreatic islet morphology. Importantly,
568 there was a clear augmentation of the biological action of
569 native GIP in high-fat-fed mice, suggestive of restored GIP
570 effectiveness by (DAla2)GIP/xenin-8-Gln. Further studies are
571 required to fully evaluate the molecular mechanisms and full
572 range of actions of (DAla2)GIP/xenin-8-Gln. However, it is
573 evident that this stable GIP/xenin hybrid may represent an
574 attractive potential new therapeutic for type 2 diabetes.
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